Hematide
 |
It has been suggested that this article or section be merged into Peginesatide. (Discuss) Proposed since December 2011. |
Hematide is an investigational synthetic peptide, substituted with polyethylene glycol (thus described as "PEGylated"). It is a novel erythropoietic agent, being an analog of erythropoietin,[1] and has been developed for medical use as a treatment for anemia,[2] now in stage 3 clinical trials. Whether it will be approved is not certain.[3]
The drugs currently used to treat anemia in the United States are epoetin alfa (which mimics the structure of the human glycoprotein which promotes red blood cell development, sold under the names Procrit and Epogen) and darboepoetin alfa (which is a more glycosylated form of epoetin, sold under the name Aranesp). There are similar biologic agents, such as Mircera, sold by Roche in Europe, however "United States patent law currently forbids their sale.[4]
[edit] References
- ^ "Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers" Blood, 15 September 2006, Vol. 108, No. 6, pp. 1830-1834. abstract
- ^ "Hematide for the Treatment of Anemia: An Expert Interview With Iain C. Macdougall, BSc, MD, FRCP" Medscape Nephrology
- ^ "Affymax wavers on forecast of Hematide approval" by Marley Seaman Associated Press, July 2, 2008 Boston.com
- ^ Judge blocks anemia drug sales by Amgen Rival" New York Times February 29, 2008. [1]
 |
This protein-related article is a stub. You can help Wikipedia by expanding it. |
